Photocure ASA (OSL:PHO)

Market Cap	1.67B
Revenue (ttm)	537.59M
Net Income (ttm)	2.12M
Shares Out	26.61M
EPS (ttm)	0.08
PE Ratio	790.16
Forward PE	120.96
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,237
Average Volume	38,663
Open	63.00
Previous Close	62.90
Day's Range	62.50 - 63.30
52-Week Range	47.60 - 71.80
Beta	0.53
RSI	66.28
Earnings Date	Apr 10, 2026

About Photocure ASA

Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus-induced cervical precancerous lesions. The company has a license agreement with Asieris MediTech Co to develop and commercialize Cevira; and a strategic agreemen...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1993
• Employees: 101
• Stock Exchange: Oslo Børs
• Ticker Symbol: PHO